Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Equity Average: 2018-2025

Historic Equity Average for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $492.5 million.

  • Arcus Biosciences' Equity Average fell 17.92% to $492.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $492.5 million, marking a year-over-year decrease of 17.92%. This contributed to the annual value of $473.5 million for FY2024, which is 15.37% down from last year.
  • As of Q3 2025, Arcus Biosciences' Equity Average stood at $492.5 million, which was down 8.80% from $540.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Equity Average ranged from a high of $819.5 million in Q1 2022 and a low of $491.0 million during Q4 2023.
  • Over the past 3 years, Arcus Biosciences' median Equity Average value was $543.0 million (recorded in 2023), while the average stood at $560.6 million.
  • In the last 5 years, Arcus Biosciences' Equity Average soared by 283.31% in 2021 and then fell by 27.58% in 2023.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Equity Average stood at $692.3 million in 2021, then fell by 2.07% to $678.0 million in 2022, then dropped by 27.58% to $491.0 million in 2023, then increased by 6.92% to $525.0 million in 2024, then decreased by 17.92% to $492.5 million in 2025.
  • Its last three reported values are $492.5 million in Q3 2025, $540.0 million for Q2 2025, and $508.0 million during Q1 2025.